ATNX Athenex Inc.

+0.38  (+3%)
Previous Close 12.74
Open 12.89
Price To Book 5.4
Market Cap 877647745
Shares 66,893,883
Volume 203,715
Short Ratio
Av. Daily Volume 314,611

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 preliminary data showed 50% PR and 50% SD among first 12 patients.
Breast cancer
Phase 1b data noted 2/6 and 3/6 PRs in first two cohorts.
Oraxol and CYRAMZA (Ramucirumab)
Gastric cancer
Phase 3 data released July 26, 2018. Primary endpoint met. Presentation at American Academy of Dermatology Annual Meeting March 2, 2019.
KX-01 (KX2-391) Ointment
Actinic keratosis
Phase 3 target enrolment met - January 9, 2019. Data due mid-2019.
Metastatic breast cancer
Clinical trials to commence 2019.
Oral Eribulin
Phase 1/2 initiation announced November 26, 2018.
Oraxol and pembrolizumab (Keytruda)
Solid Tumors

Latest News

  1. Athenex, Inc. to Report Fourth Quarter and Fiscal Year 2018 Earnings Results on March 11, 2019
  2. Athenex Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting
  3. Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings
  4. Athenex Completes Enrollment Target for Breast Cancer Study
  5. Buffalo startups surpassed $200 million in VC and angel funding in 2018
  6. Athenex Announces Completion of Target Enrollment in the Oraxol Phase III Study
  7. Teresa Bair talks about the big year ahead for Athenex
  8. Chongqing Jingdong Pharmaceutical and Athenex Announce a Strategic Partnership and Licensing Agreement to Develop and Commercialize KX2-391 in China
  9. Athenex Pharmaceutical Division, an Athenex, Inc. Company, Launches Levothyroxine Sodium for Injection
  10. What Kind Of Shareholders Own Athenex, Inc. (NASDAQ:ATNX)?
  11. Company News For Dec 13, 2018
  12. CORRECTION: Athenex Announces Positive Second Cohort Results of Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in Gastric Cancer
  13. Athenex Announces Positive Second Cohort Results of Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in Gastric Cancer
  14. Recent Analysis Shows Athenex, National CineMedia, Macy's, Manulife Financial, CBS, and Strategic Education Market Influences — Renewed Outlook, Key Drivers of Growth
  15. Athenex to Host an R&D Day on December 17 in New York
  16. Athenex Announces Licensing Agreement with PharmaEssentia for Rights to Oradoxel (Oral Docetaxel) in Certain Asian Territories
  17. Athenex Announces Initiation of a Phase I/II Clinical Study of Oraxol in Combination with Anti-PD1
  18. Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $117,500 of Shares
  19. Edited Transcript of ATNX earnings conference call or presentation 14-Nov-18 1:00pm GMT
  20. Athenex: 3Q Earnings Snapshot